StockData
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc. (CAI) stock

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 8/30131% above fair value
$34.33−1.81 (-5.01%)

Close on Oct 30, 2026Market cap $9.70BP/E –Yield –

Earnings

Caris Life Sciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 4, 2026
Q3 FY2026 · estimated, during market hours
Revenue, Q2 FY2026
$263.70M
+45.4% on a year earlier
EPS, Q2 FY2026
–
-$7.97 a year earlier
Latest guidance
Raised
Aug 5, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Caris Life Sciences's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 4, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 5, 2026during market hours$263.70M+45.4%–Release
Q1 FY2026ended Mar 31, 2026May 7, 2026during market hours$216.20M––Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026during market hours$292.90M–$0.28Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025during market hours$216.80M–$0.08Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025during market hours$181.40M–-$7.97Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Caris Life Sciences's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueFY2026$1.03B – $1.04B$1.00B – $1.02BRaisedAug 5, 2026
revenueFY2026$1.00B – $1.02B–NewFeb 26, 2026
revenue growthFY2026+27% – +28%–NewAug 5, 2026
Clinical therapy selection volumeFY2026+20%–NewFeb 26, 2026
clinical therapy selection volume growthFY2026+20%+20%ReaffirmedAug 5, 2026
GAAP operating expensesGAAPFY2026$590.00M – $595.00M–NewFeb 26, 2026
Molecular profiling revenueFY2026+21% – +22%–RaisedFeb 26, 2026
Molecular profiling revenue growth excluding out-of-year revenue from over collections recorded in 2025non-GAAPFY2026+26% – +28%–NewFeb 26, 2026
Pharma & research revenueFY2026$75.00M – $85.00M–NewFeb 26, 2026

Guidance history

Every forecast Caris Life Sciences put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 5, 2026clinical therapy selection volume growthFY2026+20%Reaffirmed
Aug 5, 2026revenueFY2026$1.03B – $1.04BRaised
Aug 5, 2026revenue growthFY2026+27% – +28%New
May 7, 2026clinical therapy selection volume growthFY2026+20%New
May 7, 2026revenueFY2026$1.00B – $1.02BNew
Feb 26, 2026Molecular profiling revenue growth excluding out-of-year revenue from over collections recorded in 2025FY2026+26% – +28%New
Feb 26, 2026GAAP operating expensesFY2026$590.00M – $595.00MNew
Feb 26, 2026Pharma & research revenueFY2026$75.00M – $85.00MNew
Feb 26, 2026Molecular profiling revenueFY2026+21% – +22%Raised
Feb 26, 2026Clinical therapy selection volumeFY2026+20%New
Feb 26, 2026revenueFY2026$1.00B – $1.02BNew
Nov 5, 2025Clinical therapy selection volumeFY2025+21% – +22%New
Nov 5, 2025revenueFY2025+75% – +77%New
Nov 5, 2025revenueFY2025$720.00M – $730.00MNew
Aug 12, 2025Clinical therapy selection volumeFY2025+19% – +21%New
Aug 12, 2025revenueFY2025$675.00M – $685.00MNew
Aug 12, 2025revenue growthFY2025+64% – +66%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Caris Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
    Results
  2. Caris Life Sciences Reports First Quarter 2026 Financial Results
    Results
  3. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
    Results
  4. Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results
    Results
  5. Caris Life Sciences Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
    Results
  6. Caris Life Sciences Reports Second Quarter 2025 Financial Results
    Results